SOUTH SAN FRANCISCO, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a biopharmaceutical company developing novel treatments for nonalcoholic steatohepatitis (NASH), and other serious immuno-inflammatory and fibrotic diseases, will report financial results for the quarter ended June 30, 2015 after market close on Tuesday, November 10, 2015. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Listen via Internet: http://ir.tobiratherapeutics.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 64027659.
About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at www.tobiratherapeutics.com.
CONTACT: Tobira Investor & Media Contact: Ian Clements, PhD +1 (650) 351-5013 email@example.com Canale Communications Media Contact: Pam Lord +1 (619) 849-6003 firstname.lastname@example.orgSource:Tobira Therapeutics, Inc.